Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03801434
Title Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stanford University
Indications

hypereosinophilic syndrome

chronic eosinophilic leukemia

Therapies

Ruxolitinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Cancer Institute Palo Alto Recruiting Palo Alto California 94304 United States Details
OHSU Knight Cancer Institute Recruiting Portland Oregon 97201 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field